ReviewDiabetes, metabolic syndrome and obesity : targets and therapy2026
Efficacy and Safety of Acupoint Catgut Embedding for Obesity Associated with Polycystic Ovary Syndrome: A Qualitative and Quantitative Analysis.
Review in Diabetes, metabolic syndrome and obesity : targets and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aim: Obesity is common in women with polycystic ovary syndrome (PCOS) and can exacerbate PCOS symptoms. Although Acupoint catgut embedding (ACE) is frequently used to treat the clinical symptoms of simple obesity, it is unclear how it will affect obesity associated with PCOS. We conducted a systematic review and meta-analysis of randomized clinical trials (RCTs) to evaluate the effectiveness of ACE in treating obesity in women with PCOS. Methods: We searched databases from inception to January 8, 2025. Two independent reviewers extracted data and assessed the risk of bias. All meta-analyses used random effects models, and the GRADE approach was used to assess the certainty of the evidence. Results: We included 25 RCTs (1,663 participants). Based on usual care, compared to blank treatment, ACE probably reduces body mass index (BMI), waist-to-hip ratio (WHR), and waist circumference (WC), and may enable a greater proportion of patients to achieve a weight loss no less than 5% (relative risk [RR] 1.33, 95% CI 1.15 to 1.55) and may reduce triglycerides (TG). Furthermore, when compared to active comparators, ACE probably enables a greater proportion of patients to achieve a weight loss no less than 5% (RR 1.40, 95% CI 1.11 to 1.76) and reduces WC and may also reduce BMI and TG. All effects were supported by low to moderate certainty evidence. Conclusion: When compared to blank treatment, on the basis of usual care, ACE for obesity associated with PCOS may improve obesity-related outcomes. When compared to active comparators, it may have comparable or greater therapeutic efficacy and fewer adverse events. Such improvements in obesity-related indicators may help alleviate metabolic and reproductive symptoms in women with PCOS. As all included trials were conducted in China, further high-quality studies in diverse populations are needed to confirm the generalizability of these findings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.